Phase I study of pazopanib plus TH-302 in advanced solid tumors. - Wikidata - wikimedia - TriplyDB

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

http://www.wikidata.org/entity/Q33439635

about

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

http://www.wikidata.org/entity/Q33439635

description

2017 nî lūn-bûn

@nan

2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

@ast

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

@en

type

label

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

@ast

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

@en

prefLabel

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

@ast

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

@en

P1433

Q33439635-165CAC75-249E-4ABA-B6B4-EB807DDDB785

P1476

Q33439635-3C516750-1C3B-4D0E-B2DB-C2E94A060CFC

P2093

Q33439635-46A60196-B033-445F-AEF6-9A99E901372E

Q33439635-4F2E1FC3-19B2-43E9-8C08-BCA234979EC6

Q33439635-603BCF7E-D4CC-4296-9D4C-64BFDA9E81AA

Q33439635-6247B2D8-B5CF-4069-8A2D-08CA73A8D811

Q33439635-6E7DDF4A-DFFA-4DA6-B22A-E0EA68C7D082

Q33439635-7114BDAC-DE3B-41AC-BBA4-8115D723A103

Q33439635-7501EA07-BA72-4D55-8A23-5BF41866387C

Q33439635-8FC495FE-6803-451C-9A46-AE52230F3ECA

Q33439635-A69798BC-3E5B-4D56-89C9-E545E73751CF

Q33439635-C7524F29-9E47-4E8E-9DB9-06714AAFA4EC

P2860

Q33439635-056A09C0-7B59-47C3-9B0F-D8D5CCA1F7B9

Q33439635-07A3A7A2-84FB-4CCA-BC7A-2A24EC6835EF

Q33439635-2E7341D9-B6C6-4466-A154-D93A78944A48

Q33439635-432E5343-C272-4879-890E-06EA910E3683

Q33439635-444EB5C7-DB15-45CF-B678-09DE7247AA6E

Q33439635-45229AE9-E244-49BE-BA64-F690BE9D6F64

Q33439635-475CD3BC-558E-4958-AEAE-B82A74CBD167

Q33439635-493717D5-17FA-4A00-8CAE-958D51841581

Q33439635-52456433-8A61-4250-896B-E565F6D2219E

Q33439635-56C5D03C-54B4-475C-A169-74B86C320615

P2888

Q33439635-0E036E0C-1E65-46C5-9DF0-DA05639874E9

P304

Q33439635-A106471F-17AC-43D3-AD31-A989C06C7FE7

P31

Q33439635-ECABE244-6F29-4D2D-85FC-5F9579925392

P356

Q33439635-E9435EA0-191B-41A2-B803-70DDECCD8BE3

P433

Q33439635-C87B0047-24B2-4009-86C3-F50DFE79F361

P478

Q33439635-0C5009A5-4952-4A1A-AD6E-3DEFE212A5DA

P50

Q33439635-D1BEB4A3-3AF3-4CB4-B8D8-4ED53C8CD157

P577

Q33439635-037704CB-70BA-4344-BD75-6677654080E1

P6179

Q33439635-3BE8230E-6707-4D6B-8306-F2B81C6D6D16

P698

Q33439635-26FD35FA-2284-4246-8270-A801A2EF008C

P356

S00280-017-3256-2

P1433

Cancer Chemotherapy and Pharmacology

P1476

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

@en

P2093

Christel N Rushing

http://www.w3.org/2001/XMLSchema#string

Christy C Arrowood

http://www.w3.org/2001/XMLSchema#string

Daniel J George

http://www.w3.org/2001/XMLSchema#string

Gerard C Blobe

http://www.w3.org/2001/XMLSchema#string

Herbert I Hurwitz

http://www.w3.org/2001/XMLSchema#string

Hope E Uronis

http://www.w3.org/2001/XMLSchema#string

Jeffrey Crawford

http://www.w3.org/2001/XMLSchema#string

Kellen L Meadows

http://www.w3.org/2001/XMLSchema#string

Michael A Morse

http://www.w3.org/2001/XMLSchema#string

Paula H Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

TGFbeta in Cancer

Hypoxia--a key regulatory factor in tumour growth

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.

Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

Hypoxia, inflammation, and the tumor microenvironment in metastatic disease

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

P2888

s00280-017-3256-2

P304

611-619

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-017-3256-2

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P50

Donna Niedzwiecki

P577

2017-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1083921282

http://www.w3.org/2001/XMLSchema#string

P698

28238078

http://www.w3.org/2001/XMLSchema#string